Equillium Plummets 21% on Cryptocurrency Pivot – Biotech Bet or Financial Gamble?
-
最新报道：Equillium's stock plunged 21% after announcing a pivot from biotech to cryptocurrency, sparking investor concerns over the abrupt strategic shift. The clinical-stage company, previously focused on autoimmune diseases, revealed plans to explore blockchain and digital assets, citing "transformative potential." Analysts question the move, noting Equillium lacks crypto expertise and faces stiff competition in the volatile sector. The downturn reflects broader market skepticism about traditional firms entering Web3 without clear roadmaps. CEO Jason Keyes defended the decision as "forward-looking," but shareholders remain wary of the high-risk financial gamble amid the company's ongoing clinical trials.
下一篇
U.S. Dollar Reserve Status Debated as Economic Burden Not Boon
- The debate over the U.S. dollar's reserve currency status intensifies as economists weigh ...
24小时热点
热点专题
416533